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Abstract
Background: Budesonide and formoterol (BF) Spiromax® is a dry powder inhaler designed to deliver BF with
maximum ease of use for patients with asthma or chronic obstructive pulmonary disease.
Methods: A phase 3b, 12-week, multicenter, double-blind, double-dummy, randomized, controlled trial in patients
(≥12 years) with persistent asthma. Primary objective: to demonstrate non-inferiority of twice-daily BF Spiromax
160/4.5 mcg to BF Turbuhaler® 200/6 mcg in change from baseline in weekly average of daily trough morning peak
expiratory flow (PEF). Secondary endpoints included: Patient Satisfaction and Preference Questionnaire scores,
change from baseline in evening PEF, trough forced expiratory volume in one second, percentage of symptom-free
and rescue-free 24-hour periods, and safety.
Results: The analysis was based on the per-protocol population (BF Spiromax, n = 290; BF Turbuhaler, n = 284).
The least squares mean change from baseline to week 12 in morning PEF was: BF Spiromax, 18.8 L/min and BF
Turbuhaler, 21.8 L/min. Non-inferiority of BF Spiromax vs BF Turbuhaler was demonstrated (the lower limit of the
95 % two-sided confidence interval was −9.02 L/min, which is greater than −15 L/min [the criteria specified for
non-inferiority]). The mean difference in the total performance domains scores for BF Spiromax vs BF Turbuhaler
were 0.248 at baseline and 0.353 at week 12 (both, p <0.001), indicating statistical superiority for BF Spiromax. No
statistical or numerical differences were recorded in the total convenience domain score between the two devices.
Scores for ‘device preference’ and ‘willingness to continue’ supported BF Spiromax at baseline and at week 12 (p = 0.0005
vs BF Turbuhaler). No significant between-group differences were observed in the other secondary efficacy endpoints.
Both treatments were well tolerated, with no significant differences in adverse events or asthma exacerbations.
Conclusions: This study demonstrates the non-inferiority of BF Spiromax vs BF Turbuhaler in patients (≥12 years) with
asthma. More patients preferred the Spiromax device over Turbuhaler for its performance, and were willing to continue
therapy with BF Spiromax beyond the 12-week study period.
Trial registration: NCT01803555; February 28, 2013.
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Background
The benefits of inhaled therapy for the treatment of
chronic obstructive airway diseases including asthma
and chronic obstructive pulmonary disease (COPD) are
well established. Long-term controller medications, such
as inhaled corticosteroids (ICS) are used with the aim of
achieving daily control of asthma symptoms and pre-
venting exacerbations. The addition of a long-acting β2
agonist (LABA) to ICS therapy is more effective than
increasing the dose of ICS for patients with moderate-
to-severe asthma who are symptomatic despite low- to
medium-dose ICS [1]. The fixed-dose combination
(FDC) of the ICS/LABA, budesonide–formoterol (BF)
fumarate dihydrate, has shown greater improvement in
pulmonary function and overall asthma control com-
pared with either individual compound alone [2–4].
The therapeutic efficacy of an inhalation therapy such
as BF requires that the drug/s reach the lower lung (spe-
cifically the smaller airways of the lungs). As such, not
only the prescribed medication, but also the inhaler de-
vice plays an important role in the efficacy of drug deliv-
ery to the lungs and subsequent improvement of asthma
control [5]. In the European Union, the FDC of BF is ad-
ministered via a dry powder inhaler (DPI) and its approval
includes use for the long-term, twice-daily, maintenance
treatment of asthma. DPIs were developed with the aim of
simplifying the inhalation process compared with the
available pressurized metered dose inhalers (pMDIs).
pMDIs require coordination with actuation; the patient
needs to press down the canister and inhale the medica-
tion simultaneously. DPIs are breath-activated (most
pMDIs are not), precluding the need to coordinate actu-
ation with inhalation and may therefore be easier to use
[6–8]. Although DPIs might be perceived by patients to be
easier to use compared with pMDIs, many patients still
have difficulties in using DPIs correctly. This may lead to
loss of asthma control, or increased frequency and severity
of current asthma symptoms [5]. Providing patients with
the option of using a device that is easier to use may
facilitate the correct handling of the inhaler and can en-
sure that the prescribed medication reaches the targeted
areas of the lung [5].
The Spiromax device is a DPI that uses a novel X-
ACT® technology [9]. The DuoResp® Spiromax formula-
tion (BF Spiromax FDC) has been approved for use in
the European Union for the treatment of adults
(≥18 years old) with asthma and for patients with COPD
for whom an ICS/LABA combination is indicated [10].
BF Spiromax is indicated for the long-term, twice-daily,
maintenance treatment of asthma or COPD as mainten-
ance and as an ‘as-needed’ reliever for asthma.
The bioequivalence of medium- and high-strength BF
Spiromax to BF Turbuhaler was previously demon-
strated [11]. Here, we present results from a phase 3b
study (A Spiromax Safety and Efficacy Trial [ASSET])
where the efficacy, safety and patient-reported outcomes
of BF Spiromax (160/4.5 mcg [medium strength]) were
compared with BF Turbuhaler (200/6 mcg [medium




This was a randomized, double-blind, double-dummy,
multicenter, parallel-group, 12-week, phase 3b study
comprising a 14-day (±2 days) run-in period and a 12-
week double-blind treatment period (NCT01803555/
BFS-AS-306 [ASSET]; Fig. 1). The primary objective of
the study was to establish the non-inferiority of BF
Spiromax (160/4.5 mcg) to BF Turbuhaler (200/6 mcg)
administered twice-daily for 12 weeks in patients aged
≥12 years with persistent asthma. As a secondary object-
ive, patient preference and ease of use of the Spiromax
device compared to Turbuhaler was assessed.
Independent ethics committee permission was ob-
tained prior to commencement of the study (Additional
file 1), and the study was conducted in accordance with
good clinical practice and the declaration of Helsinki.
Fig. 1 Study design. BF budesonide–formoterol, BID twice daily. aPermitted asthma therapies: fluticasone propionate, beclomethasonedipropionate,
budesonide, flunisolide, triamcinolone acetonide, mometasone furoate, ciclesonide
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All study participants, and parents/guardians of minors
participating, provided signed, informed consent.
Inclusion/exclusion criteria
Key inclusion criteria: male or female patients ≥12 years
old with a diagnosis of asthma in accordance with the
Global Initiative for Asthma [1], and Asthma Control
Questionnaire (ACQ) score of ≥1.0 at the screening visit;
persistent asthma (with a forced expiratory volume in
1 s [FEV1] of 40–85 % of the predicted value, as per the
National Health and Nutrition Examination Survey III
reference values) for ≥3 months that had been stable for
at least 30 days before the screening visit; a ≥12 % re-
versibility of FEV1 within 30 min after two to four inha-
lations of salbutamol/albuterol; or documented ≥12 %
reversibility of FEV1 (and 200 mL increase) within the
last 12 months. Any prior or concomitant therapy, medi-
cation or procedure a patient took within 90 days prior
to study drug administration, or during the study period,
was documented by the investigator. Patients must have
received a short-acting β2 agonist (SABA) and an ICS
for a minimum of 8 weeks before the screening visit,
have been maintained on a stable dose of ICS for 4 weeks
before the screening visit, and must have been able to
replace their current SABA with salbutamol/albuterol
for use as needed throughout the study.
Key exclusion criteria included: a history of life-
threatening asthma; actual or suspected bacterial or viral
infection of the upper or lower respiratory tract, sinus,
or middle ear infection within the last 2 weeks prior to
screening; an asthma exacerbation requiring oral corti-
costeroids within 1 month prior to the screening visit.
The use of oral or depot corticosteroids within 4 weeks
before the screening visit and the use of tobacco prod-
ucts within the past 12 months, or a smoking history of
≥10 pack years were prohibited. In addition, patients
were asked to not engage in strenuous exercise and to
avoid cold air exposure on the mornings of scheduled
clinic visits.
Study treatments
Patients, enrolled from outpatient clinics (at hospital or
private pulmonary specialist practices; the study took
place from July 2013 to March 2014), were randomly
assigned (1:1) to receive one of two treatments taken by
two inhalations, twice daily for 12 weeks (Fig. 1): BF
Spiromax (160/4.5 mcg) plus placebo Turbuhaler − the
Spiromax group, or BF Turbuhaler (200/6 mcg) plus pla-
cebo Spiromax − the Turbuhaler group.
Patients were randomly assigned to treatment through
a qualified randomization service provider (interactive
response technology [IRT]). This system was used to en-
sure a balance across treatment groups; no effort was
made to maintain a balance among treatment groups
within an investigational center. Patients and materials
number were centrally randomized and distributed using
the IRT. The randomization code was generated by the
Clinical Supply Chain (CSC) department following specifi-
cations from the Biostatistics Department. A statistician
not assigned to the study was responsible for reviewing
the randomization code, and the final randomization code
was maintained by the CSC department. BF Spiromax and
placebo Spiromax were presented in a Spiromax inhal-
ation device, contained in a sealed foil pouch, and packed
in an individual carton. Similarly, BF Turbuhaler and pla-
cebo Turbuhaler were presented in a Turbuhaler inhal-
ation device and packed in an individual carton. To
maintain the study blinded there was no discernible differ-
ences between BF Spiromax and placebo Spiromax or BF
Turbuhaler and placebo Turbuhaler; both were identically
labeled for each inhaler. Patients in each arm randomly
chose which device they used first (placebo or active).
Study assessments
Lung function was measured by spirometry tests. Pa-
tients were required to record daily morning (ante meri-
diem [AM]) and evening (post meridiem [PM]) asthma
symptom scores, AM and PM peak expiratory flow
(PEF) values, and medication administration in the paper
diaries provided. The asthma symptom scores were re-
corded on a linear scale from 0 to 5 (PM assessment)
where 0 = no symptoms during the day and 5 = symp-
toms so severe that the patient could not go to work or
perform normal daily activities, and from 0 to 4 (AM as-
sessment) where 0 = no symptoms during the night and
4 = symptoms so severe that the patient did not sleep at
all. The PEF was measured twice-daily by the patient
using a hand-held electronic peak flow meter. Peak flow
measurements were performed at each of the participat-
ing centers using the center’s own equipment, which
were calibrated daily. Three measurements were taken
and the highest value was recorded (the two largest
FEV1 values had to be within 150 mL of each other).
The best result, according to the American Thoracic
Society/European Respiratory Society criteria [12], was
recorded and used in the analysis.
The pulmonary function tests (FEV1 and PEF) were
measured in the morning by spirometry at the clinic
visits within ± 1 h of the time of the spirometry testing
at the screening visit.
Patients completed the ACQ [13] at each visit to pro-
vide an assessment of clinical impairment due to asthma
and any change in asthma control. Additionally, the
Patient Satisfaction and Preference Questionnaire for In-
halation Devices (PASAPQ© [Copyright by Boehringer
Ingelheim International GmbH 2004]) [14] and a ques-
tion on satisfaction with the overall quickness of using
the inhaler were completed for each device at baseline
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(day 1 of week 1 of the double-blind treatment period)
and at the end of the study. The Asthma Quality of Life
Questionnaire (AQLQ) [15, 16] was completed at base-
line and at subsequent visits.
Patient compliance to administration of study medica-
tion was assessed at each visit by reviewing patient diar-
ies for completion of the study procedure entries and by
dose counter readings on the inhaler devices.
Serial spirometry, with pulmonary function (FEV1 and
PEF) tests being performed from 30 min before dosing
to 3 h after dosing, was conducted in a planned subset
of 30 patients from three to four sites at the baseline
visit (visit 2). Drug safety was monitored throughout the
study by recording of adverse events (AEs) by the inves-
tigator (all reported or observed signs and symptoms
were recorded individually, except when considered
manifestations of a medical condition or disease state).
When such a diagnosis was made, this was recorded col-
lectively as a single diagnosis in the case report form
provided and, for serious AEs (SAEs), this was recorded
on the Serious Adverse Event Transmittal Form. Meas-
urement of vital signs and oropharyngeal examination
for candidiasis, clinical laboratory testing (blood eosino-
phil count and serum human chorionic gonadotropin
levels [as appropriate]) was conducted at screening and
at the final clinic visit.
Endpoints
The primary efficacy endpoint for this study was the
change from baseline in weekly average of daily trough
(pre-dose and pre-rescue bronchodilator) AM PEF over
the 12-week treatment period. Secondary efficacy end-
points were: PASAPQ scores and inhaler quickness satis-
faction score at week 12, the change from baseline in
weekly average of daily PM PEF, trough (AM pre-dose
and pre-rescue bronchodilator) FEV1 over the 12-week
treatment period, and percentage of symptom-free and
rescue-free 24-hour periods during the 12-week treat-
ment period.
Statistical analysis
The sample size and power calculations were based on the
non-inferiority comparison of change from baseline in
weekly average of daily trough AM PEF between BF
Spiromax and BF Turbuhaler. Two hundred and seventy
patients per treatment group (a total of 540 patients) were
required to provide an approximate statistical power of
90 % at a significance level of 0.025 for the one-sided non-
inferiority test. Non-inferiority was defined as the lower
limit of the two-sided 95 % confidence interval (CI) for
the treatment difference in change from baseline in the
weekly average of daily trough AM PEF over the 12-week
treatment period greater than −15 L/min.
The intent-to-treat population included all randomized
subjects. The per-protocol (PP) population included data
from all randomized subjects obtained before experien-
cing major protocol deviations/violations. The efficacy
analyses were conducted on the PP population. The
safety population included all randomized subjects who
received at least one dose of study medication.
The change from baseline in weekly average of daily
trough AM and PM PEF over the 12-week treatment
period was performed using a repeated measures mixed
model with adjustment for baseline weekly average of
daily trough AM or PM PEF, sex, age, treatment, time
and treatment-by-time interaction.
The change from baseline in the percentage of
symptom-free 24-hour periods and the change from base-
line in the percentage of rescue-free 24-hour periods, dur-
ing the 12-week treatment period, were analyzed using the
Wilcoxon–Mann–Whitney test.
The change from baseline in trough (AM pre-dose
and pre-rescue bronchodilator) FEV1 over the 12-week
treatment period were analyzed using a repeated mea-
sures mixed model with effects due to baseline trough
FEV1, gender, age, visit, treatment, and visit-by-
treatment interaction.
Total and individual satisfaction scores (PASAPQ per-
formance and convenience domain scores at baseline
and at week 12) were analyzed using the paired t-test.
The change from baseline in the device preference cat-
egory score, overall inhaler quickness satisfaction score,
and the ‘willingness to continue’ using the device score




Patients were enrolled from out-patient clinics (part of a
hospital or from pulmonary specialist private practices;
the study tool place from July 2013 to March 2014). A
total of 605 patients were randomized: 303 in the BF
Spiromax group and 302 in the BF Turbuhaler group.
Three patients who were randomized to the BF Turbu-
haler 200/6 mcg did not receive treatment (due to
randomization error, ‘withdrawal by subject’, and ‘other’
reason, each n = 1). The safety population included 602
patients, and the PP population included 574 patients
(Fig. 2). Compliance to the study medication in the
safety population was 97.71 % in the BF Spiromax group
and 97.49 % in the BF Turbuhaler group. Patient demo-
graphics per treatment group are shown in Table 1. The
median age of patients were 48 and 47 years for the BF
Spiromax and Turbuhaler groups, respectively; 43 and
47 % were male, and 98 and 99 % were white. There
were no significant/statistical differences between the
two groups across all parameters assessed in Table 1.
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Pulmonary function tests
As shown in Fig. 3, the mean change from baseline in
the weekly average of daily trough AM PEF, the primary
endpoint for this study, was 18.8 L/min for BF Spiromax
and 21.8 L/min for BF Turbuhaler (p = 0.3387). The
lower bound of the two-sided 95 % CI for the treatment
difference was −9.02 L/min, which is greater than
−15.0 L/min, the criteria specified for non-inferiority for
this study. Therefore, non-inferiority of BF Spiromax
(160/4.5 mcg) vs BF Turbuhaler (200/6mcg) has been
Fig. 2 Patient disposition. AE adverse event, BF budesonide–formoterol, ITT intent-to-treat, PP per protocol. aInclusion criteria not met, n = 25;
exclusion criteria met, n = 6; withdrawal by patient, n = 6; AEs, n = 1; other, n = 16. bInclusion criteria not met, n = 5; withdrawal by patient, n = 5;
randomization criteria not met, n = 2; AE, n = 1; lost to follow-up, n = 1; other, n = 52. cProtocol violation, n = 3; withdrawal by subject, n = 3; AE,
n = 2; asthma exacerbation, n = 1; non-compliance, n = 1; other, n = 3. dProtocol violation, n = 5; withdrawal by subject, n = 3; AE, n = 2; lost to
follow-up, n = 2; non-compliance, n = 1; other, n = 5. eThree patients who were randomized to the BF Turbuhaler 200/6 mcg did not receive
treatment (due to randomization error, ‘withdrawal by subject’, ‘other’ reasons; each, n = 1)
Table 1 Summary of baseline characteristics and demographic data (ITT population)
BF Spiromax (n = 303) BF Turbuhaler (n = 302)
Age, years (mean ± SD) 48.1 ± 16.24 46.9 ± 16.89
Sex, n (%)
Male 131 (43) 141 (47)
Female 172 (57) 161 (53)
Race, n (%)
White 297 (98) 300 (>99)
Black 2 (<1) 1 (<1)
Asian 1 (<1) 1 (<1)
Other 3 (<1) 0 (0)
Weight, Kg (mean ± SD) 77.4 ± 17.25 78.6 ± 17.88
Median weekly averaged AM PEF, L/min (range) 318.6 (82.9–632.9) 345.7 (108.6–604.3)
Median weekly averaged PM PEF, L/min (range) (L/min) 328.6 (98.6–650.0) 352.9 (127.1–635.7)
Median baseline FEV1, L (range) (L) 2.1 (0.9–4.2) 2.3 (0.8–4.0)
Prior asthma medications, ≥5 % (n [%])
Salbutamol 290 (96) 281 (93)
Budesonide 145 (48) 139 (46)
Fluticasone 77 (25) 73 (24)
Budesonide–formoterol 48 (16) 43 (14)
Fluticasone and salmeterol 43 (14) 37 (12)
Average symptom-free 24-hour period, % (mean ± SD) 19 ± 31.67a 15.3 ± 26.4b
Average rescue-free 24-hour period, % (mean ± SD) 33.3 ± 38.26a 30.9 ± 37.02b
AM ante meridiem (morning), BF budesonide–formoterol, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, PEF peak expiratory flow, PM post meridiem
(evening), SD standard deviation
an = 290 (per-protocol population)
bn = 284 (per-protocol population)
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achieved. In both treatment groups, there was an im-
provement in the weekly average of daily trough AM
PEF over the 12-week treatment period (Fig. 3).
The mean change from baseline in the weekly average
of daily trough PM PEF and the least squares mean
changes in FEV1 over the 12-week treatment period was
also similar for both treatment groups. The change in
daily trough PM PEF was 18.661 L/min for BF Spiromax
and 21.740 L/min for BF Turbuhaler (95 % CI: −8.82,
2.67; p = 0.2930). In both treatment groups, an improve-
ment in weekly average of daily trough PM PEF was
noted. The least squares mean changes in FEV1 from
baseline were 0.325 and 0.318 L for BF Spiromax
and BF Turbuhaler, respectively (95 % CI: −0.04,
0.06; p = 0.7661; Fig. 4).
Serial spirometry – subset analysis
Following the first dose, more patients with BF Spiromax
vs BF Turbuhaler had an increase of ≥12 % above their
baseline FEV1 for up to 6 h (16 [94 %] vs 12 [71 %] pa-
tients, respectively). Of those patients who had a ≥12 %
increase in FEV1, there was no notable difference in the
onset time when this increase occurred (0.6 and 0.9 h in
the BF Spiromax vs BF Turbuhaler groups, respectively).
The duration of the effect was comparable between the
BF Spiromax and the BF Turbuhaler (4.4 vs 3.8 h with
BF Spiromax vs BF Turbuhaler, respectively).
Asthma symptoms and rescue medication
When patients were assessed for their asthma symptoms
and rescue medications use, no significant differences
were observed between the two treatment groups. The
change from baseline to week 12 in the mean percentage
of symptom-free 24-hour periods was 30.0 % for the BF
Spiromax and 32.5 % for BF Turbuhaler (p = 0.3082).
The change in percentage of rescue-free 24-hour periods
from baseline to week 12 was also similar for both treat-
ment groups: BF Spiromax 37.8 %, BF Turbuhaler
40.2 % (p = 0.4300). There was an increase from baseline
in the mean percentage of rescue-free 24-hour periods
in both treatment groups (baseline/week 12: 33.3 %/
71 % BF Spiromax and 30.9 %/71.1 % BF Turbuhaler).
There were no significant differences between ACQ and
AQLQ scores with BF Spiromax compared with BF
Turbuhaler over the 12-week treatment period.
Patient satisfaction and preference
In general, the differences between the groups in
PASAPQ domains scores were small. The mean differ-
ence in the total performance domains scores for BF
Spiromax vs BF Turbuhaler were 0.248 and 0.353 at
baseline and week 12, respectively (both, p <0.001), indi-
cating statistical superiority for the Spiromax device in
the total performance domains scores. Similar findings
were recorded when comparing the mean differences in
individual performance domains scores (PASAPQ Q1
−Q5, Q10, and Q11) for Spiromax vs Turbuhaler. The
Spiromax device was superior to the Turbuhaler device
at baseline and week 12 for each of the individual per-
formance domains scores (the value for Spiromax
PASAPQ performance domain score minus Turbuhaler
PASAPQ performance domain score was in the positive
range; p ˂0.0001 [except for Q1, p = 0.0003]; Fig. 5a).
The mean differences in the total convenience domains
scores for Spiromax vs Turbuhaler were 0.023 (p =
0.3432) at baseline and 0.023 (p = 0.4190) at week 12,
Fig. 3 Mean change in average weekly morning PEF. AM ante meridiem (morning), BF budesonide–formoterol, PEF peak expiratory flow, SD
standard deviation. Data shown are mean change from baseline on weekly average values. Error bars represent SD. an = 290 at baseline; dropped
to n = 263 by week 12. bn = 284 at baseline; dropped to n = 256 by week 12
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indicating no statistical or numerical differences between
the two devices in the total convenience domain scores.
An analysis of the individual components of the con-
venience domains scores (PASAPQ Q6−Q9, Q12−Q13;
Fig. 5b) between the two devices revealed that the Spiro-
max device was superior to Turbuhaler (the value for
Spiromax PASAPQ convenience domain score minus
Turbuhaler PASAPQ convenience domain score was in
the positive range) at baseline and week 12 for Q6 (in-
struction for use), Q8 (durability of the inhaler), Q9
(ease of cleaning the inhaler) and Q12 (ease of holding
during use). Conversely, Turbuhaler was superior to
Spiromax (the value for Spiromax PASAPQ convenience
domain score minus Turbuhaler PASAPQ convenience
domain score was in the negative range) at baseline and
week 12 for Q7 (size of the inhaler) and Q13 (conveni-
ence of carrying) of the convenience domains scores
(Fig. 5b). The change in PASAPQ ‘willingness to continue’
use score from baseline to week 12 was significantly
greater for the Spiromax device than for Turbuhaler (3.65
vs −3.951; p = 0.0005). Device preference was higher for
the Spiromax device vs the Turbuhaler device at baseline
and week 12. At baseline, 256 patients preferred the
Spiromax device vs 126 patients who preferred Turbuhaler
(p <0.0001). At week 12, 304 patients preferred the
Spiromax device vs 118 who preferred the Turbuhaler
device (p <0.0001). The device preference for the Spiromax
vs the Turbuhaler was maintained when the population
was evaluated according to age group (Fig. 6). The
change in overall inhaler quickness satisfaction from base-
line to week 12 was significantly greater for the BF the
Spiromax than for the BF Turbuhaler (0.316 vs −0.012;
p = 0.0005).
Safety
The incidence of AEs was similar between the two treat-
ment groups; at least one AE was reported by 39 % of pa-
tients in the BF Spiromax group and by 35 % in the BF
Turbuhaler group. Details of these AEs are shown in
Table 2. Nasopharyngitis and headache were the most
common AEs reported in both study groups. SAEs were
experienced by <1 % of patients in the BF Spiromax group
and by 2 % in the BF Turbuhaler group. There were four
SAEs, all of which were deemed unrelated to the study
intervention by the investigator: one patient (<1 %) in the
BF Spiromax study group experienced pneumonia and
three patients (1 %) in the Turbuhaler study group experi-
enced a bradycardia episode leading to discontinuation, an
intervertebral disc protrusion, and a supraventricular
tachycardia (n = 1 each).
Two patients in each study group discontinued treat-
ment due to AEs. In the BF Spiromax group, one patient
Fig. 4 Mean change in trough FEV1. BF budesonide–formoterol, FEV1 forced expiratory volume in 1 s, SD standard deviation.
an = 290 at baseline;
dropped to n = 276 by week 12. bn = 284 at baseline, dropped to n = 264 by week 12
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discontinued treatment due to bacterial respiratory tract
infection and another patient discontinued treatment
due to dyspnea. In the BF Turbuhaler group, one patient
discontinued treatment due to nasopharyngitis, dyspnea,
oropharyngeal pain, and rhonchi and a second patient
discontinued treatment due to serious bradycardia (re-
ported by the same patient mentioned above in the SAE
section). There were no deaths reported in this study.
Discussion
ASSET is the first clinical study designed to compare the
efficacy and safety of BF Spiromax with BF Turbuhaler
in adult and adolescent patients with persistent asthma.
It demonstrated that BF Spiromax was non-inferior to
treatment with BF Turbuhaler with respect to the mean
change from baseline in the weekly average of daily
trough AM PEF (the relationship between the variability
Fig. 5 Differences in mean Spiromax PASAPQ scores vs mean Turbuhaler PASAPQ scores at baseline* and week 12* (a) performance domains (b)
convenience domains. BFT budesonide–formoterol Turbuhaler, BFS budesonide–formoterol Spiromax, PASAPQ Patient Satisfaction and Preference
Questionnaire for Inhalation Devices. Positive Y-axis values indicate that Spiromax performed better than Turbuhaler; negative Y-axis values
indicate that Turbuhaler performed better than Spiromax
Fig. 6 Device preference by age group at baseline and week 12
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of the PEF 20 L/Min and the non-inferiority reference
value 15 L/Min was based on a non-inferiority limit of a
value equating to a third of the assumed standard devi-
ation of the PEF at any given time point, which was set at
45 L/min). Similar improvements in FEV1 were achieved
with both devices.
BF administered in a FDC is an established and effect-
ive therapy with a long-standing, good safety profile for
the treatment of asthma [17] and COPD [4, 18]. In our
study, BF Spiromax showed similar efficacy (lung func-
tion and symptom control) and safety compared to BF
Turbuhaler over the 12-week treatment period. Further-
more, serial spirometry in a subset of patients performed
to test and compare the formoterol portion of the com-
bination showed that the time to onset (increase [from
baseline] in FEV1 of ≥12 %) and the duration of this ef-
fect were similar between the devices, further supporting
the therapeutic equivalence of BF Spiromax to BF
Turbuhaler.
Although the efficacy and safety of a medication are
important considerations when selecting a treatment for
asthma or COPD, the effectiveness of therapy is also
dependent on the patient using their inhaler correctly
and as prescribed every time. In addition, the choice of
an inhaler device and the patient’s opinion on a particu-
lar device are also important factors in asthma manage-
ment [1]. However, many patients with asthma have
poor adherence to therapy. According to the medication
adherence taxonomy recommended by Vrijens et al.
[19], poor or non-adherence in the context of patients
with asthma is one or a combination of the following:
(1) not taking medication at the correct time (example:
twice-daily regimens – patient should normally separate
each dose by ~12 h) or late in taking the treatment as
prescribed (e.g. ‘missing a dose’); (2) suboptimal imple-
mentation of the dosing regimen (e.g. not using the in-
haler correctly); and (3) early discontinuation of treatment
(e.g. the patient stops taking the medication) [19]. In
asthma, poor adherence can lead to loss of asthma control
and/or worsening of asthma symptoms [1, 20]. The ultim-
ate goal of treatment is optimal pharmacotherapy due to
its implicit association with optimal clinical outcomes –
this requires good medication adherence [19]. An inhaler
that is easy to use, carry, and store, and that is reliable and
intuitive might improve patients’ adherence.
Compared to the Turbuhaler device, which requires a
number of steps for actuation (removing the cap, hold-
ing the inhaler in an upright position and turning the
grip as far as it will go and back), the Spiromax device
has the theoretical advantage of being more intuitive
and easier to use as it can be ready for actuation after
the single step of opening the cap. Therefore, in this
study, patients were asked to provide feedback with
regards to the performance and convenience of the
Spiromax and Turbuhaler devices (at baseline and after
12 weeks) using the validated PASAPQ. The outcomes
from the PASAPQ analysis indicate that Spiromax was
superior to Turbuhaler for all performance domain
questions asked. However, no statistical or numerical
differences were observed between the two devices when
comparing the total convenience scores. When assessing
the individual device convenience scores, Spiromax was
also superior to Turbuhaler at baseline and week 12 for
its ‘instruction for use’, ‘durability of the inhaler’, ‘ease of
Table 2 AEs in ≥2 % of patients (safety population)
Number (%) patients
BF Spiromax 160/4.5 mcg BF Turbuhaler 200/6 mcg Total
(n = 303) (n = 299) (N = 602)
Patients with at least one AE 117 (39) 106 (35) 223 (37)
Infections and infestations 61 (20) 69 (23) 130 (22)
Nasopharyngitis 31 (10) 25 (8) 56 (9)
Rhinitis 6 (2) 7 (2) 13 (2)
Bronchitis 3 (<1) 7 (2) 10 (2)
Respiratory, thoracic and mediastinal disorders 33 (11) 22 (7) 55 (9)
Cough 11 (4) 8 (3) 19 (3)
Oropharyngeal pain 7 (2) 5 (2) 12 (2)
Dysphonia 9 (3) 1 (<1) 10 (2)
Nervous system disorders 21 (7) 26 (9) 47 (8)
Headache 18 (6) 24 (8) 42 (7)
Gastrointestinal disorders 18 (6) 14 (5) 32 (5)
General disorders and administration site conditions 9 (3) 4 (1) 13 (2)
AE adverse event, BF budesonide–formoterol
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cleaning’, and ‘ease of holding during use’, which might
be related to the reduced number of steps required up
to the point when actuation of the BF dose from
Spiromax can occur. On the other hand, the Turbuhaler
was deemed superior to Spiromax for its size and ‘con-
venience of carrying’. Patients were more willing to ‘con-
tinue use’ of the Spiromax device compared with
Turbuhaler (after the 12-week treatment period) and re-
ported ‘preference’ for the Spiromax device over the Tur-
buhaler. These results might reflect the more intuitive
handling of Spiromax and could have positive implications
for future adherence to treatment.
Among the strengths of this study is the assessment of
patient preference via the validated PASAPQ in addition
to assessment of clinical efficacy. Not all phase 3 con-
trolled studies consider patients’ opinions and instead
focus on clinical efficacy and safety only. The ASSET
study was conducted to reassure physicians and other
healthcare professionals (HCPs) of the practicability of
Spiromax in terms of its patient-reported ‘greater ease of
use’ (preference, ‘willingness to continue’ use and per-
formance) and its similarity to BF Turbuhaler in clinical
efficacy and safety (incidence/frequency of AEs/vital
signs, etc.). However, it should be noted that these data
were collected as part of a phase 3, controlled, clinical
trial in patients with asthma, which limits the transfer-
ability of the results to everyday practice. In the ‘real
world’, the asthma population is more heterogeneous
and disease monitoring is according to physicians’ rou-
tine clinical practice (vs a clinical trial setting).
Ultimately, real-world effectiveness trials will be
needed to determine if these improvements can lead to
improved adherence and clinical outcomes. Data from
real-world studies where patients would be randomly al-
located to receive treatment with either Spiromax or
Turbuhaler would be of particular interest in the context
of this study. Such real-word effectiveness studies are re-
quired to determine whether improvements based on
patients’ preference and satisfaction with the Spiromax
inhaler would lead to improved adherence and clinical
outcomes in real-world scenarios. Detailed patient and
HCP opinion regarding the ‘ease of use’ of the Spiromax
device vs Turbuhaler and also the proportion of pa-
tients achieving mastery (absence of observed errors)
in Spiromax/Turbuhaler inhaler technique are being
assessed in separate studies [21].
Conclusions
BF Spiromax 160/4.5 mcg was shown to be similar to BF
Turbuhaler 200/6 mcg in relation to efficacy and safety
in the treatment of asthma; however, specific domains of
the PASAPQ showed greater benefits with Spiromax
over Turbuhaler. The PASAPQ analysis suggests that
Spiromax was superior to Turbuhaler for all the
performance domains. No differences (statistical or nu-
merical) were observed when comparing the total con-
venience scores for Spiromax and Turbuhaler. Patients
preferred the Spiromax over the Turbuhaler and consid-
ered it easier to use. Studies looking to substantiate pa-
tient preference, inhaler ease of use and inhaler handling
errors (critical and non-critical errors) comparing BF Spir-
omax and Turbuhaler are currently ongoing and will clar-
ify if the benefits observed in this trial are repeated.
Ultimately, real-world effectiveness trials will be needed to
determine if these improvements can lead to improved ad-
herence and clinical outcomes.
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